Sign In
Buy CMPS
$12.69
-0.640 (-4.80%)
At Close: Jun 03, 2026
Psychedelics stocks rise after Trump order expands research, access pathways
05:56am, Monday, 20'th Apr 2026
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
04:12pm, Saturday, 18'th Apr 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the
Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
06:30am, Tuesday, 14'th Apr 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
06:30am, Wednesday, 08'th Apr 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 07'th Apr 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways (NASDAQ:CMPS) & Elevance Health (NYSE:ELV) Financial Comparison
01:33am, Friday, 03'rd Apr 2026
Elevance Health (NYSE: ELV - Get Free Report) and Compass Pathways (NASDAQ: CMPS - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses base
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
07:30am, Tuesday, 24'th Mar 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways Eyes Rolling FDA Filing for COMP360, Preps TRD Launch Ahead of Q3 Data
01:03am, Saturday, 21'st Mar 2026
Compass Pathways (NASDAQ: CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch preparation for its investigational psilocybin therapy, COMP360, during a recent
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
06:30am, Thursday, 12'th Mar 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways Highlights Phase 3 COMP360 TRD Gains, 26-Week Durability and FDA Path at Conference
02:02am, Tuesday, 10'th Mar 2026
Executives from Compass Pathways (NASDAQ: CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in treatment-resistant depression (TRD), highlighting statistically significant impr
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
06:30am, Thursday, 26'th Feb 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tod
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
06:39am, Tuesday, 24'th Feb 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise
11:14am, Friday, 20'th Feb 2026
Treatment-Resistant Depression (TRD) stands as one of the most stubborn and costly challenges in modern healthcare. For the millions of patients who have cycled through multiple antidepressants withou
Cathie Wood Pours $24 Million to This AI Software Stock
10:01am, Friday, 20'th Feb 2026
Cathie Wood's ARK Invest added to Figma (FIG) and trimmed DraftKings (DKNG) on Feb. 19, as part of a broader portfolio reshuffle.ARK funds bought about $24 mill
Compass Pathways Announces Pricing of $150 Million Public Offering
08:18pm, Wednesday, 18'th Feb 2026
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of i
